BI 3034701

BI 3034701

Evidence & Status

  • Moderate Evidence
  • Moderate

At a Glance

An experimental GLP-1/GIP/Y2 triple agonist being studied for obesity. Early human testing has been completed, and a Phase 2 weight-loss study is underway. It is not FDA approved.

Plain English

BI 3034701 is being studied as another next-generation obesity drug. Like some newer weight-loss medicines, it activates more than one biological pathway. It combines GLP-1 and GIP signaling with the Y2 receptor, which is involved in hunger and food intake. Researchers are now testing whether that combination can produce meaningful weight loss in people. We do not yet have completed Phase 2 results.

Overview

BI 3034701 is an investigational triple-receptor peptide being developed for obesity and overweight. It targets the GLP-1, GIP, and neuropeptide Y2 (NPY2/Y2) receptors. Unlike retatrutide, its third target is the Y2 receptor rather than the glucagon receptor. The compound has completed first-in-human Phase 1 testing and entered Phase 2 clinical development, but human efficacy results from the Phase 2 program are not yet available.

Research Summary

BI 3034701 is an investigational GLP-1/GIP/NPY2 triple-receptor agonist developed from Gubra-originated technology and advanced clinically by Boehringer Ingelheim. A first-in-human Phase 1 trial, NCT06352437, evaluated single and multiple subcutaneous doses in healthy participants and people with overweight or obesity. The study enrolled 125 participants and was completed in October 2025. Its primary focus included safety and tolerability, with pharmacokinetic measures including plasma exposure and maximum concentration. ClinicalTrials.gov currently lists no posted study results. A Phase 2 dose-finding trial, NCT07662122, began in June 2026. It is a randomized, double-blind, placebo-controlled, 42-week study evaluating subcutaneous BI 3034701 in adults with obesity or overweight. The latest registry information reports 342 actual participants. The study is active, not recruiting, with primary completion estimated for August 2027. Gubra and Boehringer Ingelheim have described encouraging Phase 1 weight-loss observations in company communications, but numerical human efficacy claims should not be treated as established evidence until sufficiently detailed primary clinical results or peer-reviewed data are available.

Research Areas

  • Obesity
  • Weight management
  • Metabolic research
  • Appetite regulation
United States
Investigational; not FDA-approved.
United Kingdom
Current authorization status not established in this record
Australia
Current authorization status not established in this record
Canada
Current authorization status not established in this record

Citations & Sources